Pharmacokinetics of tilmicosin in chicken joints based on a novel microdialysis sampling method

Abstract

AbstractMicrodialysis is a continuous direct sampling technique used in live animals to study pharmacokinetic (PK) characteristics of drugs directly in target organs. The antibiotic tilmicosin used to treat arthritis in chickens caused by Mycoplasma synoviae. However, the PK study of tilmicosin in chicken joint has not been reported. The aim of this study was to explore the PK characteristics and penetration of tilmicosin by microdialysis incorporated with High‐Performance Liquid Chromatography Mass Spectrometry (HPLC‐MS/MS). An articular cavity microdialysis sampling model was established by determining in vivo and in vitro recovery results. Tilmicosin was orally administered to chickens and flow rate testing combined with retro‐dialysis were used to determine tilmicosin concentration in the target synovial space. HPLC‐MS/MS quantification of tilmicosin from plasma and joint dialysate indicated that recovery was negatively correlated with flow rate and the optimal perfusion rate was determined to be 1.0 μL/min. The AUC, Cmax, MRT and t1/2 in plasma were 4.6, 3.0, 2.2 and 1.6 times higher than in the joint dialysate, respectively, but Tmax did not significantly differ. The penetration of tilmicosin from plasma to joint (AUCdialysate/AUCplasma) was 0.24 and indicated tilmicosin concentration in joints was much lower than that of plasma. Microdialysis technology provides a novel technique to study pharmacokinetics directly in target tissues and our study provides a reference for the clinical use of tilmicosin for treatment of M. synoviae infections in articular cavities.